GlobeNewsWire
19 Jul 2026, 12:42 UTC · 1d ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
ADMA Biologics is facing a securities class action lawsuit alleging the use of channel stuffing to inflate revenue. — Allegations of revenue manipulation via channel stuffing directly challenge the integrity of the company's financial reporting and growth claims.
-0.60The lawsuit claims ADMA Biologics engaged in undisclosed related party transactions and lacked adequate internal controls. — Weak internal controls and undisclosed related party transactions suggest corporate governance failures and potential financial instability.
-0.40The lead plaintiff deadline for the ADMA Biologics securities class action is August 10, 2026. — This is a procedural milestone that keeps the legal risk active in the public eye but does not inherently change the company's fundamentals.
-0.10Which stocks this story touches
Continue reading
6 related stories
Search tags
The company is facing a securities class action lawsuit alleging channel stuffing, undisclosed related party transactions, and lack of internal controls.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
29m ago
